BioScale opens MA facility; Immune System doubles patient recruitment for Ph2 trial;

@FierceBiotech: Type I diabetes nasal vaccine on the horizon. Article | Follow @FierceBiotech

@JohnCFierce: I hate to see "miracle treatment" in a headline about a scientific breakthrough. Ain't no such thing. | Follow @JohnCFierce

> BioScale has opened a new 30,000 square foot laboratory and manufacturing facility in Lexington, MA. The new facility will be used for R&D, instrument manufacturing and development. BioScale release

> Immune System Therapeutics is doubling its patient recruitment for a Phase II multiple myeloma trial. The company will add 27 more patients to the trial, which comes after positive data from the first six patients treated with the company's monoclonal antibody therapy. Release

> SCOLR Pharma has closed a $1 million sale of 8% Senior Secured Convertible Debentures, which can be converted into stock. Another $750,000 could be raised be selling similar debentures by June 30. SCOLR release

> Stockholders of Dublin, CA-based SuperGen approved issuing shares in connection with the company's acquisition of Astex Therapeutics. SuperGen release

Pharma News

@FiercePharma: Are drugmakers suffering from complexity? Item | Follow @FiercePharma

> CMS keeps status quo on Amgen's anemia meds. Story

> NICE favors drugs from Celgene, GSK-Valeant. Report

> FDA: Pfizer's Chantix may boost heart risks. News

> High Court clears way for Baycol class action. Item

> Pharma marketers band together on social media. Article

And Finally... University of Michigan researchers have developed a noninvasive brain implant, called BioBolt, that could someday allow paralyzed patients to translate their thoughts into actions. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.